Uncategorized

• 28th Apr 2025

  Challenges and solutions to the sustainability of gene and cell therapies

• 10th Mar 2025

  A Perspective on ‘Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare Diseases’

• 7th Feb 2025

  Review of a ‘systematic review of challenges and opportunities in the implementation of managed entry agreements for advanced therapy medicinal products’

• 9th Dec 2024

  Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe

• 30th Sep 2024

  The ISPOR value flower: application to advanced therapy medicinal products

• 17th Apr 2024

  Value assessment of advanced therapies: improving patient access to innovative treatments

• 28th Feb 2024

  Should the value of advanced therapies fall under a subjective or objective category? Brief philosophical musings. 

• 30th Jan 2024

  Assessing the value of advanced therapies

• 12th Apr 2022

  Brief considerations on the value assessment of advanced therapy medicinal products

• 5th Sep 2021

  The potential misnomer of health economics and outcomes research